Difference between revisions of "Mapatumumab (HGS-ETR1)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | =Mechanism of action= | + | ==Mechanism of action== |
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) | Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) | ||
+ | |||
+ | ==Also known as== | ||
+ | *'''Code name:''' HGS-ETR1 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
− | [[Category: | + | [[Category:Intravenous medications]] |
+ | |||
[[Category:Anti-TRAIL-R1 antibodies]] | [[Category:Anti-TRAIL-R1 antibodies]] | ||
− | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 13:56, 16 December 2020
Mechanism of action
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1)
Also known as
- Code name: HGS-ETR1